) This core is intended to be a resource for the SPORE as a whole and a valuable source of biological materials for the present and future projects and pilot studies. The laboratory core will be responsible for the collection, storage, and distribution of ovarian tissues and tumors. Fresh/frozen samples will be collected at FCCC and other participating sites and forwarded to our core laboratory. This laboratory core will also be responsible for the collection of archival ovarian tumor specimens and the extraction of DNA to be distributed to the participating projects and pilot studies. It is estimated that more than 400 new ovarian cancers cases will be identified each year through the OCCN (see Core 1) during the course of our proposal. It is very conservatively estimated that approximately 30 percent of these cases will be accrued as fresh/frozen specimens. Paraffin embedded tumors will be available from all cases. Tumor samples will be used by Projects 1, 2, 3 and 5. In addition, we will collect ovaries removed for prophylaxis from women considered to be at increased risk of developing ovarian cancer (e.g., BRCA1, BRCA1 mutant allele carriers, or suggestive family history of cancer) who participate in our chemoprevention trial (see Project 4). These tissues will be processed and distributed for pathology and immunohistochemical evaluation to determine the effect of fenretinide and other chemopreventive agents on the cancer-prone phenotype that we have previously observed in at risk ovaries. By centralizing these services into a core, we will be better able to manage and coordinate the collection, storage, and distribution of a large number of highly valuable tumor, cancer-prone and normal specimens.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fox Chase Cancer Center
United States
Zip Code
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 24:3513-3527.e7
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 25:1384
Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G et al. (2018) NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene 37:4854-4870
Chiang, Cheryl Lai-Lai; Kandalaft, Lana E (2018) In vivo cancer vaccination: Which dendritic cells to target and how? Cancer Treat Rev 71:88-101
Beck, Tim N; Smith, Chad H; Flieder, Douglas B et al. (2017) Head and neck squamous cell carcinoma: Ambiguous human papillomavirus status, elevated p16, and deleted retinoblastoma 1. Head Neck 39:E34-E39
Yang, Lu; Zhang, Youyou; Shan, Weiwei et al. (2017) Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med 9:
Skates, Steven J; Greene, Mark H; Buys, Saundra S et al. (2017) Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res 23:3628-3637
Zhang, Dongmei; Zhang, Gao; Hu, Xiaowen et al. (2017) Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer. Cancer Res 77:3745-3757
Prudnikova, Tatiana Y; Chernoff, Jonathan (2017) The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin. Small GTPases 8:193-198

Showing the most recent 10 out of 323 publications